BSE filing, NSE: INDOCO. Summary written from the filing by ALFA Finder's alert engine.
Indoco Remedies Ltd: key numbers
- Share price
- ₹213.75
- Market cap
- ₹1,973 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 61.8×Sector 46.1×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Q2 FY27 Results: Turns Profitable, Net Profit ₹19.5 Cr
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹19.5 Cr
Indoco Remedies Employee Stock Options
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Board Meeting Date
Indoco Remedies intimated a board meeting on 27 Oct 2026 to approve Q1 FY27 standalone and consolidated results. Trading window remains closed until 29 Oct 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.